세계의 금 나노입자 시장 : 프로세스별, 용도별, 최종 이용 산업별, 지역별 - 예측(-2029년)

Gold Nanoparticles Market by Process (Physical, Chemical, Biological), Application (Imaging, Targeted Drug Delivery, Proton Therapy, In-Vitro Assays, Sensors, Probes, Catalysis), End-Use Industry and Region - Global Forecast to 2029

US $ 4,950 ￦ 7,181,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,648,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,824,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,509,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

금 나노입자 시장 규모는 2024년에 5억 달러에 달했습니다.

이 시장은 2024년부터 2029년까지 16.3%의 연평균 복합 성장률(CAGR)을 나타내고, 2029년에는 11억 1,000만 달러에 달할 것으로 예상됩니다. 이는 확장성, 비용 효율성, 입자 크기, 모양, 표면 기능의 정밀한 제어와 같은 특성 때문입니다. 이는 금 나노입자를 제조하는 제조업체들 사이에서 가장 인기 있는 선택입니다. 물리적 또는 생물학적으로 가공된 다른 나노입자와 달리 화학적으로 가공된 금 나노입자는 상업적 응용에 이상적인 고수율 생산과 안정적인 품질을 제공합니다. 화학적으로 처리된 금 나노입자는 제약 및 헬스케어, 전기 및 전자, 화학, 퍼스널케어 및 화장품 등 다양한 최종 사용 산업에서 사용되고 있습니다.

조사 범위
조사 대상 연도	2021-2029년
기준 연도	2023년
예측 기간	2024-2029년
검토 단위	금액(100만 달러), 수량(KG)
부문별	공정별, 용도별, 최종 이용 산업별, 지역별
대상 지역	유럽, 북미, 아시아태평양, 중동/아프리카, 남미

양성자 치료는 금 나노입자 시장에서 가장 높은 시장 점유율을 차지할 것으로 예상됩니다. 양성자 치료는 암 방사선 치료의 획기적인 발전 중 하나입니다. 양성자 치료는 그 발전에도 불구하고 정확성과 효과에 대한 문제에 직면해 있지만, 최근 연구에 따르면 금 나노입자가 양성자 치료의 결과를 향상시킬 수 있는 잠재력이 강조되고 있습니다. 금 나노입자는 높은 원자번호와 유리한 생물학적 특성을 가지고 있으며, 양성자 조사 시 2차 전자와 활성산소종의 발생을 증폭시킴으로써 방사선 증감제 역할을 합니다. 이를 통해 건강한 조직을 보존하면서 종양 세포의 DNA 손상을 강화합니다. 이처럼 금 나노입자는 양성자선 치료를 강화하는 중추 역할을 합니다.

2024년부터 2029년까지 예측 기간 동안 금 나노입자 시장의 최종 이용 산업에서 제약 및 헬스케어 산업이 가장 높은 시장 점유율을 차지할 것으로 예상됩니다. Gilead Sciences, Inc. 및 GSK plc와 같은 주요 제약회사들은 백신 개발 및 키트에 금 나노입자를 채택하고 있으며, 이러한 제약 및 헬스케어 산업에서 금 나노입자 수요는 생체 적합성, 광학 특성, 표면 특성 등의 우수한 성능 특성으로 인해 증가하고 있습니다. 제약 및 헬스케어 최종 이용 산업은 높은 성장률로 성장하고 있으며, 금 나노입자의 소비를 증가시킬 것으로 예상됩니다.

아시아태평양은 금 나노입자와 같은 고성능 재료의 원동력인 제약 및 헬스케어 분야 수요 증가로 인해 금 나노입자 시장이 가장 빠르게 성장하고 있는 지역입니다. 이 지역은 다양한 응용 분야에서 금 나노입자를 종합적으로 사용하고 있는 대형 제약업체 Sun Pharmaceutical Industries Ltd, Sapien Biosciences가 독점하고 있습니다. 아시아태평양에는 세계에서 가장 인구가 많은 인도, 중국 등 주요 국가들이 있으며, 의약품 및 의료 수요에 대한 수요가 증가하는 추세입니다. 둘째, 아시아태평양에는 ARITECH CHEMAZONE PVT LTD, Oparin Biotech Pvt Ltd와 같은 다양한 금 나노입자 제조업체가 있습니다.

세계의 금 나노입자 시장에 대해 조사했으며, 공정별, 용도별, 최종 이용 산업별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• Porter의 Five Forces 분석
• 주요 이해관계자와 구입 기준
• 거시경제 지표
• 생성형 AI의 영향
• 밸류체인 분석
• 생태계 분석
• 사례 연구 분석
• 규제 상황
• 기술 분석
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 무역 분석
• 2024-2025년 주요 컨퍼런스 및 이벤트
• 가격 분석
• 투자와 자금조달 시나리오
• 특허 분석

제6장 금나노입자 시장(프로세스별)

• 서론
• 물리적 프로세스
• 화학적 프로세스
• 생물학적 프로세스

제7장 금나노입자 시장(용도별)

• 서론
• 이미징
• 표적 약물전달
• 양자선 치료
• 체외분석(In-Vitro Assays)
• 센서
• 프로브
• 촉매
• 기타

제8장 금나노입자 시장(최종 이용 산업별)

• 서론
• 의약품 및 헬스케어
• 전기 및 전자
• 화학제품
• 퍼스널케어 및 화장품
• 기타

제9장 금나노입자 시장(지역별)

• 서론
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 스페인
  • 영국
  • 이탈리아
  • 기타
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 기타
• 중동 및 아프리카
  • GCC 국가
  • 튀르키예
  • 남아프리카공화국
  • 기타
• 남미
  • 브라질
  • 아르헨티나
  • 기타

제10장 경쟁 구도

• 개요
• 주요 시장 진출기업의 전략
• 매출 분석, 2021년-2023년
• 시장 점유율 분석
• 기업 가치 평가와 재무 지표
• 브랜드/제품 비교 분석
• 기업 평가 매트릭스 : 주요 시장 진출기업, 2023년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
• 경쟁 시나리오와 동향

제11장 기업 개요

• 주요 시장 진출기업
  • BBI SOLUTIONS
  • CYTODIAGNOSTICS INC
  • FORTIS LIFE SCIENCES, LLC.
  • MELIORUM TECHNOLOGIES, INC
  • JOHNSON MATTHEY
  • TANAKA PRECIOUS METAL GROUP CO.
  • SIGMA ALDRICH(MERCK KGAA)
  • NANOPARTZ INC.
  • CD BIOPARTICLES
  • NANO LABS
  • NANOCS INC
• 기타 기업
  • NANOHYBRIDS
  • FORTIS LIFE SCIENCES
  • SONA NANOTECH
  • SISCO RESEARCH LABORATORIES PVT, LTD.
  • NANOPROBES, INC
  • AMERICAN ELEMENTS
  • TORSKAL
  • ABCAM LIMITED
  • PARTICULAR GMBH
  • DONGGUAN SAT NANO TECHNOLOGY MATERIAL CO., LTD
  • NANO FLOW
  • STREM CATALOG
  • NANORH
  • SKYSPRING NANOMATERIALS, INC
  • AURION
  • NNCRYSTAL US CORPORATION

제12장 부록

LSH

영문 목차

영문목차

The gold nanoparticles market is estimated at USD 0.50 billion in 2024 and is projected to reach USD 1.11 billion by 2029, at a CAGR of 16.3% from 2024 to 2029. Due to its properties such as scalability, cost effectiveness, and precise control over particle size, shape and surface functionality. It is the most popular choice among manufacturers for producing gold nanoparticles. Unlike the other nanoparticles which are physically or biologically processed, chemically processed gold nanoparticles provides high yield production and consistent quality which make them ideal for commercial applications. Chemically processed gold nanoparticles are used in various end use industries such as pharmaceuticals & healthcare, electrical & electronics, chemicals, personal care & cosmetics.

Scope of the Report
Years Considered for the Study	2021-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD Million), Volume (KG)
Segments	By Process Type, By Application, By End-Use Industry, and By Region
Regions covered	Europe, North America, Asia Pacific, Middle East & Africa, and South America

''In terms of value, proton therapy application accounted for the largest share of the overall gold nanoparticles market.''

Proton therapy application is projected to be the highest market share holding application in the gold nanoparticles market. Proton therapy is one of the groundbreaking advancements in cancer radiotherapy. Despite its advancements proton therapy faces challenges in precision and efficacy, but recent research has highlighted the potential of gold nanoparticles to enhance proton therapy outcomes. Gold nanoparticles have high atomic number and favourable biological properties through which it acts as a radiosensitizers by amplifying generation of secondary electrons and reactive oxygen species upon proton irradiation. This enhances DNA damage in tumor cells while preserving healthy tissues. Thus gold nanoparticles act as a backbone for enhancing proton therapy.

"During the forecast period, the gold nanoparticles market in pharmaceuticals & healthcare industry is projected to have highest market share."

During the forecast period from 2024 to 2029, the pharmaceuticals & healthcare industry is expected to have the highest market share in end-use industry in the gold nanoparticles market. The demand for gold nanoparticles is rising in pharmaceuticals & healthacre industry due to its superior performance characteristics, including biocompatibility, optical properties, surface properties and others. Top leading pharmaceutical manufactures such as Gilead Sciences, Inc., and GSK plc. have already adopted gold nanoparticles for vaccine development and kits. Pharmaceuticals & healthcare end use industry is tend to grow with high rate and which will increase the consumption of gold nanoparticles.

"During the forecast period, the gold nanoparticles market in Asia Pacific region is projected to be the fastest growing region."

Asia Pacific is the fastest growing market for gold nanoparticles because of its strong demand from pharmaceuticals & healthcare, which is a driving factor for high-performance materials such as gold nanoparticles. The region is dominated by large pharmaceuticals manufacturers, Sun Pharmaceutical Industries Ltd., Sapien Biosciences, which have comprehensive use of gold nanoparticles in various applications. Asia Pacific region has major countries such as India, China which has highest population in the world, and which will tend to increase the demand for pharmaceuticals & healthcare needs. Second, Asia Pacific region is home to various gold nanoparticles manufacturers such as ARITECH CHEMAZONE PVT LTD., Oparin Biotech Pvt Ltd and others.

This study has been validated through primary interviews with industry experts globally. These primary sources have been divided into the following three categories:

• By Company Type- Tier 1- 60%, Tier 2- 20%, and Tier 3- 20%
• By Designation- C Level- 33%, Director Level- 33%, and Managers- 34%
• By Region- North America- 20%, Europe- 25%, Asia Pacific- 25%, Middle East & Africa- 15%, and Latin America- 15%

The report provides a comprehensive analysis of company profiles:

Prominent companies BBI Solutions (UK), Cytodiagnostics Inc (Canada), Fortis Life Sciences, LLC. (US), Meliorum Technologies, Inc (US), TANAKA PRECIOUS METAL GROUP Co., Ltd. (Japan), Merck KGaA (Germany), Nanopartz, Inc (US), CD Bioparticles (US), Nano Labs (India), Nanocs Inc. (US), NanoHybrids (US), Sona Nanotech (Canada), Sisco Research Laboratories Pvt, Ltd. (India), Nanoprobes, Inc (US), American Elements (US), TORSKAL (France), Abcam Limited (UK), Particular GmbH (Germany), Dongguan Sat Nano Technology Material Co., Ltd (China), Nano Flow (Belgium), Strem Catalog (US), Nanorh (India), SkySpring Nanomaterials (US), Aurion (Netherlands), NNCrystal US Corporation (US).

Research Coverage

This research report categorizes the gold nanoparticles market By Process (Physical, Chemical, and Biological), By Application (Imaging, Targeted Drug Delivery, Proton Therapy, In-Vitro Assays, Sensors, Probes, Catalysis, and Other Applications), End-Use Industry (Pharmaceuticals & Healthcare, Electrical & Electronics, Chemicals, Personal Care & Cosmetics, and Other End-use Industries), Region (North America, Europe, Asia Pacific, Middle East & Africa, and South America). The scope of the report includes detailed information about the major factors influencing the growth of the gold nanoparticles market, such as drivers, restraints, challenges, and opportunities. A thorough examination of the key industry players has been conducted in order to provide insights into their business overview, solutions, and services, key strategies, contracts, partnerships, and agreements. Product launches, mergers and acquisitions, and recent developments in the gold nanoparticles market are all covered. This report includes a competitive analysis of upcoming startups in the gold nanoparticles market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall gold nanoparticles market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing demand for gold nanoparticles in electrical & electronics end use industry, unique properties of gold nanoparticles), restraints (Toxicity concerns of gold nanoparticles, stringent regulations impacting market development), opportunities (Increasing in research & development efforts in nanotechnology applications, growing demand for gold nanoparticles in various end use industries), and challenges (High time consumption for certain synthesis methods, growing cost of gold as a raw material) influencing the growth of the gold nanoparticles market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and service launches in the gold nanoparticles market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the gold nanoparticles market across varied regions.
• Market Diversification: Exhaustive information about services, untapped geographies, recent developments, and investments in the gold nanoparticles market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like BBI Solutions (UK), Cytodiagnostics Inc (Canada), Fortis Life Sciences, LLC. (US), Meliorum Technologies, Inc (US), TANAKA PRECIOUS METAL GROUP Co., Ltd. (Japan), Merck KGaA (Germany), Nanopartz, Inc (US), CD Bioparticles (US), Nano Labs (India), Nanocs Inc. (US), NanoHybrids (US), Sona Nanotech (Canada), Sisco Research Laboratories Pvt, Ltd. (India), Nanoprobes, Inc (US), American Elements (US), TORSKAL (France), Abcam Limited (UK), Particular GmbH (Germany), Dongguan Sat Nano Technology Material Co., Ltd (China), Nano Flow (Belgium), Strem Catalog (US), Nanorh (India), SkySpring Nanomaterials (US), Aurion (Netherlands), NNCrystal US Corporation (US), among others in the gold nanoparticles market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SPREAD
  • 1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
  • 1.3.5 UNIT CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of major secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
• 2.5 GROWTH RATE ASSUMPTIONS/FORECAST
  • 2.5.1 SUPPLY SIDE
    • 2.5.1.1 List of major companies
  • 2.5.2 DEMAND SIDE
• 2.6 RISK ASSESSMENT
• 2.7 LIMITATION

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN GOLD NANOPARTICLES MARKET
• 4.2 GOLD NANOPARTICLES MARKET, BY PROCESS
• 4.3 GOLD NANOPARTICLES MARKET, BY APPLICATION
• 4.4 GOLD NANOPARTICLES MARKET, BY END-USE INDUSTRY
• 4.5 GOLD NANOPARTICLES MARKET, BY REGION

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising adoption of gold nanoparticles in next-gen electronics: powering smartphones, tablets, touchscreens, and GPS technologies
    • 5.2.1.2 High demand for gold nanoparticles in pharmaceutical & healthcare end-use industry
    • 5.2.1.3 Unique properties of gold nanoparticles
    • 5.2.1.4 Growing demand for oil-soluble gold nanoparticles
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Toxicity concerns of gold nanoparticles
    • 5.2.2.2 Stringent regulations impacting market development
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increase in research & development efforts in nanotechnology applications
    • 5.2.3.2 Emerging applications in various end-use industries
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High time consumption for certain synthesis methods
    • 5.2.4.2 Growing price for gold as raw material
• 5.3 PORTER'S FIVE FORCES ANALYSIS
  • 5.3.1 THREAT OF NEW ENTRANTS
  • 5.3.2 THREAT OF SUBSTITUTES
  • 5.3.3 BARGAINING POWER OF BUYERS
  • 5.3.4 BARGAINING POWER OF SUPPLIERS
  • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.4 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.4.2 BUYING CRITERIA
• 5.5 MACROECONOMIC INDICATORS
  • 5.5.1 GLOBAL GDP TRENDS
• 5.6 IMPACT OF GEN AI
• 5.7 VALUE CHAIN ANALYSIS
  • 5.7.1 RAW MATERIAL SUPPLIERS (GOLD SOURCE & PRECURSORS)
  • 5.7.2 MANUFACTURERS (SYNTHESIS & PROCESSING)
  • 5.7.3 SUPPLIERS/DISTRIBUTORS
  • 5.7.4 END-USE INDUSTRIES
• 5.8 ECOSYSTEM ANALYSIS
• 5.9 CASE STUDY ANALYSIS
  • 5.9.1 ENHANCING CLINICAL EFFECTIVENESS OF GOLD NANOPARTICLES IN MEDICAL APPLICATIONS
  • 5.9.2 OPTIMIZING GOLD NANOPARTICLE SYNTHESIS USING DESIGN OF EXPERIMENTS (DOE)
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATIONS
    • 5.10.1.1 Europe
    • 5.10.1.2 Asia Pacific
    • 5.10.1.3 North America
  • 5.10.2 STANDARDS
    • 5.10.2.1 ISO 10993
    • 5.10.2.2 ISO/TS 27687
    • 5.10.2.3 ISO 13321
  • 5.10.3 REGULATORY BODIES, GOVERNMENT BODIES, AND OTHER AGENCIES
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Colloidal synthesis and green synthesis methods
    • 5.11.1.2 Plasmonic & optical sensing technologies
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Microfluidics & Lab-on-a-Chip Devices
  • 5.11.3 ADJACENT TECHNOLOGIES
  • 5.11.4 QUANTUM DOTS & NANOELECTRONICS
• 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.13 TRADE ANALYSIS
  • 5.13.1 EXPORT SCENARIO (HS CODE 284310)
  • 5.13.2 IMPORT SCENARIO (HS CODE 284310)
• 5.14 KEY CONFERENCES & EVENTS IN 2024-2025
• 5.15 PRICING ANALYSIS
  • 5.15.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.15.2 AVERAGE SELLING PRICE TREND, BY END-USE INDUSTRY, 2022-2029
  • 5.15.3 AVERAGE SELLING PRICE OF KEY PLAYERS, BY END-USE INDUSTRY, 2023
• 5.16 INVESTMENT AND FUNDING SCENARIO
• 5.17 PATENT ANALYSIS
  • 5.17.1 APPROACH
  • 5.17.2 DOCUMENT TYPES
  • 5.17.3 PUBLICATION TRENDS, 2013-2023
  • 5.17.4 INSIGHTS
  • 5.17.5 LEGAL STATUS OF PATENTS
  • 5.17.6 JURISDICTION ANALYSIS
  • 5.17.7 TOP COMPANIES/APPLICANTS
  • 5.17.8 TOP 10 PATENT OWNERS (US) IN LAST 10 YEARS

6 GOLD NANOPARTICLES MARKET, BY PROCESS

• 6.1 INTRODUCTION
• 6.2 PHYSICAL
  • 6.2.1 PRODUCTION OF HIGHLY UNIFORM NANOPARTICLES TO DRIVE DEMAND
• 6.3 CHEMICAL
  • 6.3.1 WIDE USE IN VARIOUS APPLICATIONS TO DRIVE DEMAND
• 6.4 BIOLOGICAL
  • 6.4.1 APPLICATIONS IN BIOMEDICINE, ENVIRONMENTAL SCIENCE, AND CATALYSIS TO DRIVE DEMAND

7 GOLD NANOPARTICLES MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 IMAGING
  • 7.2.1 INCREASING DEMAND FOR IMAGING APPLICATIONS
• 7.3 TARGETED DRUG DELIVERY
  • 7.3.1 INCREASING NEED FOR PRECISION DRUG DELIVERY WITH MINIMAL SIDE EFFECTS TO DRIVE DEMAND
• 7.4 PROTON THERAPY
  • 7.4.1 GROWING DEMAND FOR HIGHLY EFFECTIVE AND SAFER CANCER TREATMENTS TO FUEL INTEREST IN GNP-ASSISTED PROTON THERAPY
• 7.5 IN-VITRO ASSAYS
  • 7.5.1 INCREASING DEMAND FOR RAPID, POINT-OF-CARE DIAGNOSTICS, AND HIGH-THROUGHPUT SCREENING METHODS TO DRIVE MARKET
• 7.6 SENSORS
  • 7.6.1 HIGH-PERFORMANCE, PORTABLE, AND REAL-TIME SENSING TECHNOLOGIES TO DRIVE DEMAND
• 7.7 PROBES
  • 7.7.1 RISING NEED FOR HIGHLY SENSITIVE AND MULTIPLEXED DETECTION PLATFORMS TO DRIVE DEMAND
• 7.8 CATALYSIS
  • 7.8.1 HIGH STABILITY, RECYCLABILITY, AND ABILITY TO OPERATE UNDER MILD REACTION CONDITIONS TO DRIVE DEMAND FOR GOLD NANOPARTICLES IN CATALYSIS APPLICATION
• 7.9 OTHER APPLICATIONS
  • 7.9.1 GROWING NEED FOR PRECISION MEDICINE, ADVANCED BIOSENSORS, AND SUSTAINABLE SOLUTIONS TO DRIVE DEMAND

8 GOLD NANOPARTICLES MARKET, BY END-USE INDUSTRY

• 8.1 INTRODUCTION
• 8.2 PHARMACEUTICALS & HEALTHCARE
  • 8.2.1 TARGETED DRUG DELIVERY SYSTEM AND DIAGNOSTIC APPLICATIONS TO INCREASE DEMAND FOR GOLD NANOPARTICLES
• 8.3 ELECTRICAL & ELECTRONICS
  • 8.3.1 CONDUCTIVITY AND FLEXIBILITY TO DRIVE DEMAND IN ELECTRICAL AND ELECTRONICS INDUSTRIES
• 8.4 CHEMICALS
  • 8.4.1 CATALYSIS AND GREEN CHEMISTRY APPLICATION TO DRIVE DEMAND
• 8.5 PERSONAL CARE & COSMETICS
  • 8.5.1 ANTIBACTERIAL, ANTIFUNGAL, ANTI-INFLAMMATORY, AND REGENERATIVE PROPERTIES OF GOLD NANOPARTICLES TO DRIVE DEMAND
• 8.6 OTHER END-USE INDUSTRIES

9 GOLD NANOPARTICLES MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 US
    • 9.2.1.1 Growing healthcare and cosmetics industries to boost market
  • 9.2.2 CANADA
    • 9.2.2.1 Demand from growing chemical, healthcare, and cosmetics industries to propel market
  • 9.2.3 MEXICO
    • 9.2.3.1 Healthcare industry to drive market
• 9.3 EUROPE
  • 9.3.1 GERMANY
    • 9.3.1.1 Rising investment in healthcare sector to drive demand for gold nanoparticles
  • 9.3.2 FRANCE
    • 9.3.2.1 Increasing utilization of gold nanoparticles in various end-use industries to boost market
  • 9.3.3 SPAIN
    • 9.3.3.1 Opportunities in pharmaceutical & healthcare industry to fuel demand
  • 9.3.4 UK
    • 9.3.4.1 Demand for gold nanoparticles in healthcare industry to propel market
  • 9.3.5 ITALY
    • 9.3.5.1 Chemicals, pharmaceuticals, and food & beverage industries to boost demand
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
    • 9.4.1.1 High requirement of gold nanoparticles in various end-use industries to drive demand
  • 9.4.2 JAPAN
    • 9.4.2.1 Gold nanoparticles' requirement in various end-use industries to drive market
  • 9.4.3 INDIA
    • 9.4.3.1 Growth of pharmaceutical industry to increase demand
  • 9.4.4 SOUTH KOREA
    • 9.4.4.1 Strategic focus on healthcare industry to drive growth
  • 9.4.5 REST OF ASIA PACIFIC
• 9.5 MIDDLE EAST & AFRICA
  • 9.5.1 GCC COUNTRIES
    • 9.5.1.1 UAE
      • 9.5.1.1.1 Significantly expanding healthcare sector to propel market growth
    • 9.5.1.2 Saudi Arabia
      • 9.5.1.2.1 Improvised healthcare sector to drive demand
    • 9.5.1.3 Rest of GCC countries
  • 9.5.2 TURKIYE
    • 9.5.2.1 Advancement in nanotechnology to increase demand
  • 9.5.3 SOUTH AFRICA
    • 9.5.3.1 Diversified economy to drive growth
  • 9.5.4 REST OF MIDDLE EAST & AFRICA
• 9.6 SOUTH AMERICA
  • 9.6.1 BRAZIL
    • 9.6.1.1 Increasing investments in electronic industry to drive growth
  • 9.6.2 ARGENTINA
    • 9.6.2.1 Growing pharmaceutical sector to drive market
  • 9.6.3 REST OF SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES
• 10.3 REVENUE ANALYSIS, 2021-2023
• 10.4 MARKET SHARE ANALYSIS
• 10.5 COMPANY VALUATION AND FINANCIAL METRICS
• 10.6 BRAND/PRODUCT COMPARISON ANALYSIS
• 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.7.1 STARS
  • 10.7.2 EMERGING LEADERS
  • 10.7.3 PERVASIVE PLAYERS
  • 10.7.4 PARTICIPANTS
  • 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.7.5.1 Company footprint
    • 10.7.5.2 Region footprint
    • 10.7.5.3 Process footprint
    • 10.7.5.4 Applications
    • 10.7.5.5 End-use industry footprint
• 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.8.1 PROGRESSIVE COMPANIES
  • 10.8.2 RESPONSIVE COMPANIES
  • 10.8.3 DYNAMIC COMPANIES
  • 10.8.4 STARTING BLOCKS
  • 10.8.5 COMPETITIVE BENCHMARKING: KEY STARTUPS/SMES, 2023
    • 10.8.5.1 Detailed list of key startups/SMEs
    • 10.8.5.2 Competitive benchmarking of key startups/SMEs
• 10.9 COMPETITIVE SCENARIO AND TRENDS
  • 10.9.1 PRODUCT LAUNCHES
  • 10.9.2 EXPANSIONS
  • 10.9.3 DEALS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 BBI SOLUTIONS
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products/Solutions/Services offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 CYTODIAGNOSTICS INC
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products/Solutions/Services offered
    • 11.1.2.3 MnM view
      • 11.1.2.3.1 Right to win
      • 11.1.2.3.2 Strategic choices
      • 11.1.2.3.3 Weaknesses and competitive threats
  • 11.1.3 FORTIS LIFE SCIENCES, LLC.
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products/Solutions/Services offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 MELIORUM TECHNOLOGIES, INC
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products/Solutions/Services offered
    • 11.1.4.3 MnM view
  • 11.1.5 JOHNSON MATTHEY
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products/Solutions/Services offered
    • 11.1.5.3 MnM view
  • 11.1.6 TANAKA PRECIOUS METAL GROUP CO.
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products/Solutions/Services offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product Launch
    • 11.1.6.4 MnM view
      • 11.1.6.4.1 Right to win
      • 11.1.6.4.2 Strategic choices
      • 11.1.6.4.3 Weaknesses and competitive threats
  • 11.1.7 SIGMA ALDRICH (MERCK KGAA)
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products/Solutions/Services offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Expansions
    • 11.1.7.4 MnM view
      • 11.1.7.4.1 Right to win
      • 11.1.7.4.2 Strategic choices
      • 11.1.7.4.3 Weaknesses and competitive threats
  • 11.1.8 NANOPARTZ INC.
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products/Solutions/Services offered
    • 11.1.8.3 MnM view
  • 11.1.9 CD BIOPARTICLES
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products/Solutions/Services offered
    • 11.1.9.3 MnM view
  • 11.1.10 NANO LABS
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products/Solutions/Services offered
    • 11.1.10.3 MnM view
  • 11.1.11 NANOCS INC
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products/Solutions/Services offered
    • 11.1.11.3 MnM view
• 11.2 OTHER PLAYERS
  • 11.2.1 NANOHYBRIDS
  • 11.2.2 FORTIS LIFE SCIENCES
  • 11.2.3 SONA NANOTECH
  • 11.2.4 SISCO RESEARCH LABORATORIES PVT, LTD.
  • 11.2.5 NANOPROBES, INC
  • 11.2.6 AMERICAN ELEMENTS
  • 11.2.7 TORSKAL
  • 11.2.8 ABCAM LIMITED
  • 11.2.9 PARTICULAR GMBH
  • 11.2.10 DONGGUAN SAT NANO TECHNOLOGY MATERIAL CO., LTD
  • 11.2.11 NANO FLOW
  • 11.2.12 STREM CATALOG
  • 11.2.13 NANORH
  • 11.2.14 SKYSPRING NANOMATERIALS, INC
  • 11.2.15 AURION
  • 11.2.16 NNCRYSTAL US CORPORATION

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS

관련자료